Who are Botulinum Toxin Type-A (day 0)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botulinum toxin A 150u, Botulinum toxin type A injection, Botulinum Toxin Type A (Botox), Botulinum Toxin Type A 900kD, Placebo / Botulinum Toxin A, BOTULINUM TOXIN TYPE B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-toxin-type-a-day-0.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Botulinum Toxin Type-A (day 0) — Competitive Intelligence Brief

Botulinum Toxin Type-A (day 0) (Botulinum Toxin Type-A (day 0)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; neuromuscular blocking agent. Area: Aesthetics; Neurology; Ophthalmology.

marketed Neurotoxin; neuromuscular blocking agent SNAP-25 (synaptosome-associated protein of 25 kDa) Aesthetics; Neurology; Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Botulinum Toxin Type-A (day 0) (Botulinum Toxin Type-A (day 0)) — Ivo Pitanguy Institute. Botulinum toxin type-A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Botulinum Toxin Type-A (day 0) TARGET	Botulinum Toxin Type-A (day 0)	Ivo Pitanguy Institute	marketed	Neurotoxin; neuromuscular blocking agent	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum toxin A 150u	Botulinum toxin A 150u	EvergreenHealth	marketed	Neurotoxin; Acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25)
Botulinum toxin type A injection	Botulinum toxin type A injection	Hugel	marketed	Neurotoxin; botulinum toxin preparation	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A (Botox)	Botulinum Toxin Type A (Botox)	University of Utah	marketed	Neurotoxin; neuromuscular blocking agent	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kD	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Placebo / Botulinum Toxin A	Placebo / Botulinum Toxin A	Walter Reed Army Medical Center	marketed	Neurotoxin / Acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
BOTULINUM TOXIN TYPE B	BOTULINUM TOXIN TYPE B	Eisai Co., Ltd.	marketed	Neurotoxin; botulinum toxin	Synaptobrevin (VAMP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; neuromuscular blocking agent class)

Ivo Pitanguy Institute · 1 drug in this class
Lanzhou Institute of Biological Products Co., Ltd · 1 drug in this class
Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust · 1 drug in this class
University of Utah · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botulinum Toxin Type-A (day 0) — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-day-0. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab